uniQure started at buy by SunTrust

uniQure initiated with a Buy at SunTrust. As reported earlier, SunTust analyst Edward Nash initiated uniQure with a Buy rating and a price target of $48, saying the company is a “gene therapy pure play initially targeting orphan diseases”. He projects the company’s revenue for hemophilia B franchise and Huntington’s disease reaching as high as $1.4B and over $2B respectively, with 13K U.S./E.U. patients for the former and 100K patients for the latter. Nash points to Q3 start of testing for uniQure’s AMT-061 for hemophilia B as the next potential catalyst for the company

https://bit.ly/2kobH4n